Why Is CVS Group PLC Up Today?
CVS Group PLC shares rose 3.39% today to 1,249p, up 41p, according to the market data provided.
The move appears to be a partial rebound after the shares fell around 5% following the company's full-year results on 24 September. There does not appear to be a new company-specific announcement today, and the gain comes alongside a firmer session for UK mid-caps.
Investors may also be reassessing the results in light of the regulatory clarity provided by the conclusion of the Competition and Markets Authority's market investigation into veterinary services.
Key Highlights
For the year to 30 June 2026, CVS reported Revenue up 5.9% to £712.8 million, with like-for-like sales growth of 2.1%, up from 0.2% the previous year. Adjusted EPS rose 6.9% to 85.6p.
Adjusted EBITDA margins remained close to 20% despite wage Inflation and higher national insurance costs. Free Cash Flow was £69.2 million, and acquisitions totalled £43.3 million.
Australia revenue rose to £79.1 million from £52.1 million, and the region now represents about 11% of group revenue.
About CVS Group PLC
CVS is a UK-listed veterinary group operating practices in the UK and Australia. It also runs referral hospitals, diagnostic laboratories, crematoria and an online pharmacy.
The company moved from AIM to the Main Market of the London Stock Exchange and entered the FTSE 250 Index during the year.
Key Reasons Behind Today's Uptick
The selling after results reflected disappointment that like-for-like growth of 2.1% was below the company's 4% to 8% target range. Today's bounce suggests some investors see that reaction as overdone given the improving trend and regulatory certainty.
The final CMA remedies order, published on 22 September 2026, was in line with the company's expectations. Chief executive Richard Fairman said CVS is broadly comfortable with the remedies and well advanced in implementing them.
CMA Clarity Opens the Door to UK M&A
With the CMA process concluded, CVS says attractive UK Acquisition opportunities are materialising. It has exchanged contracts on a nine-vet practice for initial consideration of £15 million, with completion expected soon, and reports a growing pipeline of further UK deals.
The group has also made progress on joint branding under a national CVS Vets brand, which supports central Marketing and CRM campaigns and helps meet CMA transparency requirements.
Australia Expansion Accelerates
Australia has become a key growth engine. Acquisitions in the current and prior year, along with like-for-like growth, drove a 52% rise in revenue. CVS typically pays around six times EBITDA for Australian practices, below its implied group multiple, making the deals earnings-accretive.
Healthy Pet Club Advanced
CVS launched Healthy Pet Club Advanced in July 2026, which offers unlimited consultations. Healthy Pet Club revenue has grown from £67.3 million in 2022 to £95.5 million in 2026, although membership eased slightly to 508,000 as the company prioritised value over volume.
The new tier aims to remove cost barriers that delay treatment and support lifelong client relationships.
Growth Catalysts
Key catalysts include a recovery in UK like-for-like growth, UK and Australian acquisitions, Healthy Pet Club Advanced take-up and the ongoing £50 million share buyback, which is expected to run until November 2026.
Reform of the Veterinary Surgeons Act, which CVS supports, could modernise the profession over time.
Risks
UK consumer weakness could keep like-for-like growth below target. Implementing CMA remedies, including price transparency measures, could pressure margins. Leverage rose to around 1.63 times and is expected to move towards the 2.0 times ceiling as the buyback continues.
Wage inflation and recruitment of vets remain structural challenges.
Iran War and Its Impact on CVS Group
Veterinary care is relatively defensive, but higher energy prices linked to the Iran conflict could squeeze household budgets. With Brent Crude above $107 per barrel today, pet owners may delay non-urgent treatment, which could affect like-for-like growth.
Higher Utility costs could also affect practices, laboratories and crematoria.
Valuation
At 1,249p, CVS trades on around 14.6 times FY26 adjusted EPS of 85.6p. The valuation reflects slower UK growth, balanced against strong cash generation, acquisition opportunities and a buyback.
What Investors Should Watch Next
Investors should watch like-for-like growth in the first half of FY27, completion of UK acquisitions, Australian expansion, CMA remedy implementation and buyback progress.
Conclusion
CVS has emerged from the CMA investigation with clarity and an intact Business model. Today's rebound suggests investors are looking past a disappointing like-for-like figure towards renewed M&A, Australian growth and Shareholder returns.






Please wait processing your request...